Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) share a symptom cluster that has proven stubbornly hard to treat: profound fatigue, post-exertional malaise, and cognitive impairment often described as “brain fog.” A growing body of research points to impaired mitochondrial energy production as a shared mechanism underlying both conditions [1][2], which has led some researchers and clinicians to ask whether methylene blue, a century-old compound with a documented ability to interact directly with the mitochondrial electron transport chain, might have a role to play.
This article examines the actual state of the evidence: what is established about mitochondrial dysfunction in these conditions, what is proposed about methylene blue’s mechanism, and where genuine human trial data exists versus where the case remains mechanistic and preliminary.
Key Takeaways
- Systematic reviews document measurable mitochondrial abnormalities in ME/CFS patients compared to healthy controls, and long COVID appears to share overlapping mitochondrial signatures.
- Methylene blue can accept electrons from NADH and donate them to cytochrome c, creating an alternative pathway that may support ATP production when parts of the electron transport chain are underperforming.
- The strongest human evidence for methylene blue’s cognitive effects comes from a single randomized, placebo-controlled fMRI trial in healthy adults, not from a trial in long COVID or ME/CFS patients specifically.
- Clinical interest in methylene blue for post-COVID fatigue is currently mechanistic and case-based reasoning, not supported by dedicated randomized controlled trials in this population.
- Methylene blue’s MAO-inhibiting activity makes it dangerous to combine with SSRIs, SNRIs, or other serotonergic medications, a meaningful consideration since many long COVID and ME/CFS patients are prescribed these drugs for co-occurring depression or pain.
The Mitochondrial Dysfunction Hypothesis in ME/CFS and Long COVID
Fatigue that doesn’t resolve with rest, and that worsens after even modest physical or cognitive exertion, is the defining feature of both ME/CFS and long COVID. A 2020 systematic review of mitochondrial abnormalities in ME/CFS patients found consistent structural and functional differences compared to healthy controls, though the field has not converged on a single definitive biomarker [3]. More recent work has extended this framework directly to long COVID, proposing that impaired mitophagy, the cell’s process for clearing damaged mitochondria, creates an energetic bottleneck that becomes most apparent during exertion, closely mirroring the post-exertional malaise reported by ME/CFS patients [2].
This is the rationale that has drawn attention to methylene blue and other mitochondria-targeting compounds. If damaged or underperforming mitochondria are a driver of persistent fatigue, then a compound with a documented ability to support electron flow through the respiratory chain is mechanistically plausible as a candidate, but plausibility is not the same as proof.
How Methylene Blue Is Proposed to Help
At low doses, methylene blue can accept electrons from NADH and donate them directly to cytochrome c, effectively creating a shortcut around Complex I and Complex III of the electron transport chain. This mechanism has been reviewed extensively in the neuroprotection literature, where methylene blue’s redox cycling is described as a way to sustain mitochondrial respiration and reduce oxidative stress under conditions where normal electron flow is compromised [4]. A 2020 commentary specifically raised methylene blue as a candidate for addressing the neurocognitive impairment (“post-COVID blues”) reported by COVID-19 survivors, reasoning from the same mitochondrial-support and anti-neuroinflammatory mechanisms [1].
It is important to be precise about what this represents: a mechanistic argument and a small number of case-based clinical observations, not a completed trial in long COVID or ME/CFS patients. No large randomized controlled trial has tested methylene blue specifically for long COVID fatigue, ME/CFS, or post-exertional malaise as of this writing.
What Human Trial Data Actually Exists
The strongest human evidence for methylene blue’s cognitive effects comes from a 2016 randomized, double-blinded, placebo-controlled imaging study in 26 healthy adults. A single low dose (approximately 4 mg/kg) increased brain activity during attention and short-term memory tasks and improved memory retrieval by roughly 7% compared to placebo, measured with functional MRI [5]. This study is genuinely informative about methylene blue’s acute effects on brain metabolism and cognition in healthy people, it is not a trial in long COVID or ME/CFS patients, it did not measure fatigue or post-exertional malaise, and it involved a single acute dose rather than the sustained daily use that fatigue-focused protocols typically discuss.
This is a common pattern in emerging-interest supplement research: a real, well-designed study in one population gets cited as support for use in a different population with an overlapping but distinct mechanism. Readers researching methylene blue for long COVID or ME/CFS specifically should recognize that no equivalent trial exists yet for those conditions.
Safety Considerations Specific to This Population
Long COVID and ME/CFS patients are frequently prescribed SSRIs, SNRIs, or other serotonergic medications for co-occurring depression, anxiety, or neuropathic pain. Methylene blue is a potent monoamine oxidase inhibitor, and combining it with these medications carries a well-documented, FDA-warned risk of serotonin syndrome, a potentially fatal drug interaction. Anyone with long COVID or ME/CFS considering methylene blue should review their full medication list with a physician before use, not after starting. G6PD deficiency remains an absolute contraindication regardless of the condition being addressed, and dosing above the low, hormetic range can worsen rather than improve mitochondrial function.
A Note on the Evidence
The mitochondrial dysfunction hypothesis for both ME/CFS and long COVID is genuinely supported by a growing body of research [2][3]. Methylene blue’s mechanism of action makes it a mechanistically coherent candidate worth continued research attention. What does not yet exist is a completed clinical trial demonstrating that methylene blue reduces fatigue, improves post-exertional malaise, or measurably helps long COVID or ME/CFS patients as a population. Interest in this application should be understood as an extrapolation from mechanism and adjacent human data, not as an established, evidence-backed treatment.
Frequently Asked Questions
Is there a clinical trial testing methylene blue specifically for long COVID or ME/CFS?
Not as of this writing. The rationale for using methylene blue in these conditions comes from mitochondrial mechanism research and adjacent human cognition trials, not a dedicated randomized controlled trial in long COVID or ME/CFS patients.
Can methylene blue interact with medications commonly prescribed for long COVID or ME/CFS?
Yes, and this is one of the most important safety considerations. Methylene blue is a monoamine oxidase inhibitor and can cause serious, potentially fatal serotonin syndrome when combined with SSRIs, SNRIs, tramadol, or other serotonergic drugs frequently prescribed for co-occurring depression, anxiety, or pain in this population.
Does the human research on methylene blue and memory apply to long COVID brain fog?
The 2016 Rodriguez et al. imaging trial demonstrated improved short-term memory and attention-related brain activity after a single low dose of methylene blue in healthy adults. It did not study long COVID patients or brain fog specifically, so its findings should be considered suggestive of a broader mechanism rather than direct evidence for this use case.
What should someone with long COVID or ME/CFS do before trying methylene blue?
Review current medications for serotonergic interactions with a physician, confirm G6PD status if unknown, and understand that the evidence base for this specific application is mechanistic and preliminary rather than clinically proven.
This is informational content, not medical advice. Methylene blue is a potent drug with serious interaction risks and contraindications, and its use should be discussed with a qualified healthcare provider before starting.
References
- Evora PRB. Methylene blue: Subduing the post COVID-19 blues! Braz J Cardiovasc Surg (2020). PMID 32864945
- Reviews of mitochondrial signatures in Long COVID discuss methylene blue among candidate mitochondria-targeting therapeutics alongside urolithin A and rapamycin. PMID 39960432
- Holden S et al. A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. J Transl Med (2020). PMID 33109201
- Rojas JC, Bruchey AK, Gonzalez-Lima F. From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue. Mol Neurobiol (2017). PMID 28840449
- Rodriguez P et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology (2016). PMID 27351678
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.